Statins and cancer risk: A meta-analysis

JAMA

Volumn 295, Issue 1, 2006, Pages 74-80

  Dale, Krista M ^a,c   Coleman, Craig I ^a,c   Henyan, Nickole N ^a,c   Kluger, Jeffrey ^b,c   White, C Michael ^a,c,d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN;

BREAST CARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLON CARCINOMA; CONFIDENCE INTERVAL; DATA ANALYSIS; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HUMAN; HYDROPHILICITY; LIPOPHILICITY; LUNG CARCINOMA; MEDICAL LITERATURE; MELANOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; STATISTICAL ANALYSIS;

EID: 29944446607     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.1.74     Document Type: Review

References (48)

1. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184-2192.
2. Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C. Statins reduce breast cancer risk: a case control study in US female veterans. J Clin Oncol. 2005;23:514.
3. Khurana V, Kochhar R, Bejjanki R, Caldito G, Fort C. Statins reduce the incidence of lung cancer: a study of half a million US veterans. J Clin Oncol. 2005;23:1006.
4. Singal R, Khurana V, Caldito G, Fort C. Statins and prostate cancer risk. J Clin Oncol. 2005;23:1004.
5. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388-2394.
6. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363-2368.
7. Demierre MF. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol. 2003;21:158-165.
8. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26:883-891.
9. Kaushal V, Kohli M, Mehta P. Potential anticancer effects of statins. Endothelium. 2003;10:49-58.
10. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363:892-894.
11. Hillyard DZ, Cameron AJ, McDonald KJ, et al. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis. 2004;175:305-313.
12. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
13. Colhoun HM, Betteridge DJ, Hitman GM. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet. 2004;364:685-696.
14. Beishuizen ED, Van De Ree MA, Jukema JW, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2004;27:2887-2892.
15. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771-777.
16. Holdaas H, Fellstrom B, Jardine AG, et al; Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients. Lancet. 2003;361:2024-2031.
17. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations. Lancet. 2002;359:1379-1387.
18. Sever PS, Poulter NR, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361:1149-1158.
19. Heart Protection Study Collaborative Group. MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet. 2002;360:7-22.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998-3007.
21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER). Lancet. 2002;360:1623-1630.
22. Serruys PW, de Feyter P, Macaya C, et al; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-3222.
23. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87:1074-1079.
24. GISSI Prevenzione Investigators. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction. Ital Heart J. 2000;1:810-820.
25. The Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia. J Atheroscler Thromb. 2000;7:110-121.
26. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensinconverting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748-1754.
27. The Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
28. Bestehorn HP, Rensing UF, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease: the multicenter Coronary Intervention Study (CIS). Eur Heart J. 1997;18:226-234.
29. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
30. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
31. Shepherd J, Cobbe SM, Ford I, et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
32. Salonen R, Nyyssonen K, Porkkala-Sarataho E, Salonen J. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76:34C-39C.
33. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park J, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I). J Am Coll Cardiol. 1995;26:1133-1139.
34. Crouse JR, Byingron RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am J Cardiol. 1995;75:455-459.
35. Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest. 2004;34:21-28.
36. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
37. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
38. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
39. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
40. Bjerre LM, LeLorier J. Do statins cause cancer? a meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716-723.
41. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90:635-637.
42. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100:2308-2316.
43. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002;13:262-267.
44. Watanabe M, Koike H, Ishiba T, Okada T, Seo S, Hirai K. Synthesis and biological activity of methane sulfonyl pyrrole-substituted 3.5-dihydroxy-6 heptanoates: a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem. 1997;5:437-444.
45. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160-1164.
46. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
47. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA. 2004;291:1071-1080.
48. The Post Coronary Bypass Graft Trial Investigators. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.